Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report.
Preemptive therapy with ganciclovir has been recommended in the pediatric liver transplant strategy to avoid the development of posttransplant lymphoproliferative disorder (PTLD) from an high Epstein-Barr virus (EBV) is detected. We sought viral load to analyze the response to preemptive therapy with valganciclovir (VGC) in children with liver transplantations and an high quantitative EBV-PCR.


METHODS
From June 2005 to December 2007, we tested 979 EBV-PCR among 80 pediatric liver transplant recipients, from those 21/80 PCR were tested from the date of transplantation and 59/80 belonged to the historical cohort (7/59 had a prior history of PTLD). Patients were divided into 2 groups depending upon whether they did (n = 22) or did not (n = 19) receive VGC treatment. The response to VGC was considered complete, if the PCR was negative at 30 and 60 days of treatment; and partial, when the PCR decreased at least 50%. Ganciclovir blood levels tested in 109 cases instances and correlated with the EBV-PCR.


RESULTS
A total of 369 (33%) positive PCR were detected in 36/80 patients (mean, 75,000 copies; range = 5000-4,200,000). Among the 22 episodes treated for 30 days, 34% showed complete responses, 41%, partial, and 23%, no response. Among the non-treated group the rates were 6%, 25%, and 68%, respectively (P = .01). However, no differences were observed among those episodes treated for 60 days. At the administered doses, hardly any patient reached the recommended ganciclovir therapeutic level at 2 hours (6 micro/mL). However, the mean PCR was lower when the ganciclovir levels were greater than 4 mg/L when compared with lower levels (P = .03).


CONCLUSIONS
After 30 days of treatment there was a response to VGC in the EBV viral load. There was high interpatient variability of ganciclovir serum concentrations, suggesting the need for pharmacokinetic monitoring to optimize treatment. There was a relationship between the concentration of ganciclovir and the EBV viral load.
Venturi
C
C
Unidad de Trasplante Hepático Infantil, Hospital Universitario Valle de Hebron, Barcelona, Spain.
Bueno
J
J
Gavalda
J
J
Tórtola
T
T
Pou
L
L
Medina
A
A
Codina
G
G
Charco
R
R
Pahissa
A
A
D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D015331:Cohort Studies; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy* / Q000235:genetics; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016679:Genome, Viral / Q000187:drug effects; D004854:Herpesvirus 4, Human / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects / Q000379:methods*; D016133:Polymerase Chain Reaction / Q000187:drug effects / Q000379:methods; D012189:Retrospective Studies; D000077562:Valganciclovir; D019562:Viral Load
D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir